Monte Rosa Therapeutics, Inc. (GLUE)
13.94
+0.56
(+4.19%)
USD |
NASDAQ |
Aug 31, 16:00
13.94
0.00 (0.00%)
Pre-Market: 20:00
Monte Rosa Therapeutics Cash from Operations (Annual) : -22.80M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -22.80M |
| December 31, 2024 | 42.00M |
| December 31, 2023 | -43.80M |
| December 31, 2022 | -92.47M |
| Date | Value |
|---|---|
| December 31, 2021 | -59.36M |
| December 31, 2020 | -23.05M |
| December 31, 2019 | -6.173M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Nurix Therapeutics, Inc. | -249.46M |
| Gilead Sciences, Inc. | 10.02B |
| Ironwood Pharmaceuticals, Inc. | 127.04M |
| Capricor Therapeutics, Inc. | -69.81M |
| Cue Biopharma, Inc. | -21.69M |